Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02991339
Other study ID # ZS-SHC-DAJ
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date June 2016
Est. completion date July 2018

Study information

Verified date June 2021
Source Shanghai Zhongshan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators were aiming to evaluate whether dexamethasone administration accelerates the recovery from hepatectomy-related jaundice and decreases the rates of post-hepatectomy liver failure and its safety in the subjects who developed elevated serum total bilirubin.


Description:

Post-operative jaundice is one of the most common complications after hepatectomy for various liver tumors. Glucocorticoids, including dexamethasone, prednisolone, and methylprednisolone, were widely used to treat jaundice in the patients with severe hepatitis, liver dysfunction or liver failure. It was reported that glucocorticoids decrease the rates of liver dysfunction or mortality in those patients. However, whether post-operative glucocorticoids administration alleviated jaundice or deceased the rates of post-hepatectomy liver failure (PLF) yet to be determined. In this study, the investigators were aiming to evaluate whether dexamethasone administration accelerates the recovery from hepatectomy-related jaundice and decreases the rates of PLF and its safety in the subjects who developed elevated serum TB.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date July 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients underwent open hepatectomy for liver tumors - Preoperative liver function was Child-Pugh A, and the liver shear wave elastography (SWE) < 30 kPa - Postoperative serum total bilirubin > 2.5 ULN in 7 days after hepatectomy Exclusion Criteria: - Patients with hilar cholangiocarcinoma or other disease with obstructive jaundice - Complicating disease with severe dysfunction in respiratory or circulation system or kidney. - Patients with contraindication of glucocorticoids, including severe infection, active GI bleeding

Study Design


Intervention

Drug:
Dexamethasone
Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day

Locations

Country Name City State
China 180 Fenglin Road Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

Chen JF, Wang KW, Zhang SQ, Lei ZY, Xie JQ, Zhu JY, Weng WZ, Gao ZL, Lin BL. Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure. J Gastroenterol Hepatol. 2014 Apr;29(4):800-6. doi: 10.1111/jgh.12454. — View Citation

Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2 — View Citation

Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011 May;149(5):713-24. doi: 10.1016/j.surg.2010.10.001. Epub 2011 Jan 14. — View Citation

Thursz MR, Forrest EH, Ryder S; STOPAH investigators. Prednisolone or Pentoxifylline for Alcoholic Hepatitis. N Engl J Med. 2015 Jul 16;373(3):282-3. doi: 10.1056/NEJMc1506342. — View Citation

Yamashita Y, Shimada M, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Sugimachi K. Effects of preoperative steroid administration on surgical stress in hepatic resection: prospective randomized trial. Arch Surg. 2001 Mar;136(3):328-33. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary period in days from the day serum total bilirubin (TB) >=2.5 ULN to the day TB decreased to 1.5 ULN up to 30 days after hepatectomy
Secondary The dynamic change of serum total bilirubin up to 30 days after hepatectomy
Secondary length of hospital stay up to 30 days after surgery
Secondary inhospital expenses up to 30 days after surgery
Secondary post-operative complications, including postoperative liver failure, infection and GI bleeding up to 30 days after surgery
Secondary The dynamic change of serum glutamine aminotransferase up to 30 days after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT02041871 - Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer N/A
Recruiting NCT06044909 - Multimodal Image Registration for Helping Laparoscopic Liver Surgery Guidance
Recruiting NCT05523713 - Development and Validation of a Predictive Score for Surgical Site Infections Phase 3
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Recruiting NCT06130436 - Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy N/A
Recruiting NCT04218253 - Clinical Application of Nutrition Support Package Before Hepatectomy N/A
Recruiting NCT04559269 - Microsleep 1, Micro-sleep During Maintenance Wakefulness Tests
Completed NCT03611426 - Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy Phase 1/Phase 2
Completed NCT02817321 - Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision N/A
Recruiting NCT05598060 - Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study N/A
Completed NCT03793933 - ACS-NSQIP Calculator for Liver Surgery
Recruiting NCT03540537 - A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy N/A
Recruiting NCT06166186 - Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy N/A
Not yet recruiting NCT02758977 - Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) N/A
Completed NCT01469442 - Postoperative Biliary Fistula Prevention After Hepatectomy N/A
Completed NCT00730743 - Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection N/A
Recruiting NCT02198625 - Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication Phase 4
Completed NCT01194843 - Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations N/A
Completed NCT00200148 - Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy Phase 3